ONCOTELIC THERAPEUTCS INC (OTLC)
OTLC moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How OTLC actually reacts to news — the realized, point-in-time move the market made, measured across 153 labeled events over the last three years with zero look-ahead.
OTLC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 23% | 143 |
| 30-min | 0.00% | 21% | 145 |
| 60-min | 0.00% | 33% | 150 |
| to close | 0.00% | 46% | 153 |
| Middle 50% of OTLC reactions | -2.11% to 0.00% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 153 |
Half of all ONCOTELIC THERAPEUTCS INC news events land between -2.11% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when OTLC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to OTLC's baseline. Nothing else.
Recent OTLC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Oncotelic Therapeutics, For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.00% | |
| PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026 | Press release | GlobeNewswire | +0.00% | +0.93% | |
| Form 10-Q Oncotelic Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.25% | |
| Form 8-K Oncotelic Therapeutics, For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.70% | |
| Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th | Press release | GlobeNewswire | +10.05% | +0.54% | |
| Form D Oncotelic Therapeutics, | SEC filing · Form D | SEC EDGAR | +0.00% | -10.51% | |
| Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus) | Press release | GlobeNewswire | — | -8.94% | |
| Form 8-K Oncotelic Therapeutics, For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.36% | |
| Form 8-K Oncotelic Therapeutics, For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.36% | |
| Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway | Press release | GlobeNewswire | +0.54% | +7.32% | |
| Form 8-K Oncotelic Therapeutics, For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.81% | |
| Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003 | Press release | GlobeNewswire | +0.00% | -9.92% | |
| Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026 | Press release | GlobeNewswire | +2.01% | -7.01% | |
| Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services | Press release | GlobeNewswire | +0.00% | +9.22% | |
| Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote | Press release | GlobeNewswire | +4.06% | +8.13% | |
| NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies | Press release | GlobeNewswire | +1.47% | +0.00% | |
| Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies | Press release | GlobeNewswire | +3.90% | -5.00% | |
| Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program | Press release | GlobeNewswire | +0.00% | +17.65% | |
| Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure | Press release | GlobeNewswire | +0.00% | -13.19% | |
| Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026 | Press release | GlobeNewswire | +0.00% | +1.33% | |
| NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations | Press release | GlobeNewswire | -14.65% | -6.67% | |
| Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress | Press release | GlobeNewswire | -14.65% | -6.67% | |
| Form 10-Q Oncotelic Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -14.65% | -6.67% | |
| Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform | Press release | GlobeNewswire | -8.16% | +5.61% | |
| Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus | Press release | GlobeNewswire | — | +7.36% | |
| Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies | Press release | GlobeNewswire | +5.00% | +0.00% | |
| Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease | Press release | GlobeNewswire | +0.00% | -6.95% | |
| Form 8-K Oncotelic Therapeutics, For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.95% | |
| Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts | Press release | GlobeNewswire | +0.00% | +5.06% | |
| NetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development Pathways | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation | Press release | GlobeNewswire | +0.00% | -0.64% | |
| Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution | Press release | GlobeNewswire | -3.42% | +2.37% | |
| Form 8-K Oncotelic Therapeutics, For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | +5.49% | |
| Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress | Press release | GlobeNewswire | -10.03% | -4.09% | |
| Form 10-K Oncotelic Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.12% | +5.49% | |
| Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space | Press release | GlobeNewswire | -21.63% | -29.35% | |
| Oncotelic Therapeutics Inc. (OTCQB: OTLC) Operates at Intersection of Life Sciences, Advanced Digital Technologies, | Press release | GlobeNewswire | -4.50% | -9.00% | |
| Form 8-K Oncotelic Therapeutics, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +12.50% | -2.85% | |
| Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform | Press release | GlobeNewswire | +12.50% | -2.85% | |
| Form NT 10-K Oncotelic Therapeutics, For: Dec 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | +0.32% | |
| Form 8-K Oncotelic Therapeutics, For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.56% | |
| Form 8-K Oncotelic Therapeutics, For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.56% | |
| Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026 | Press release | GlobeNewswire | +2.38% | +0.00% | |
| Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting | Press release | GlobeNewswire | +0.00% | -3.08% | |
| NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios | Press release | GlobeNewswire | +0.00% | -0.22% | |
| Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution | Press release | GlobeNewswire | +0.00% | -7.00% | |
| Oncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset Trend | Press release | GlobeNewswire | +0.00% | -4.24% | |
| Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway | Press release | GlobeNewswire | -0.94% | -7.64% | |
| Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline | Press release | GlobeNewswire | +0.00% | +1.61% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the OTLC section they belong to.
Where else OTLC is measured.
OTLC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ONCOTELIC THERAPEUTCS INC's median reaction calculated?
Every labeled OTLC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 153 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 21% of OTLC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does OTLC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.